



## SINGAPORE INSTITUTE OF ADVANCED MEDICINE HOLDINGS LTD.

(Incorporated in the Republic of Singapore on 24 November 2011)

(Company Registration Number: 201134046D)

---

### REPAYMENT OF INTEREST ON LOANS VIA THE PROPOSED ISSUE OF AN AGGREGATE OF 2,492,362 NEW ORDINARY SHARES IN THE CAPITAL OF THE COMPANY

#### - RECEIPT OF LISTING AND QUOTATION NOTICE

---

The Board of Directors (the “**Board**” or “**Directors**”) of Singapore Institute of Advanced Medicine Holdings Ltd. (the “**Company**” and together with its subsidiaries, the “**Group**”) refers to the Company’s announcement dated 5 June 2024 (the “**Announcement**”) in relation to the repayment of Loans granted by its substantial shareholders, namely Espeetex Sdn. Bhd. (“**Espeetex**”) and Crescendas Land Corporation Pte. Ltd. (“**Crescendas**”), via the issue and allotment of an aggregate of 2,492,362 new ordinary shares in the capital of the Company (“**Shares**”) (“**Repayment Shares**”) to Espeetex and Crescendas.

*Unless otherwise defined, all capitalised terms used herein shall bear the same meanings as ascribed to them in the Announcement.*

The Board wishes to announce that the Company has on 20 June 2024 received the listing and quotation notice (“**LQN**”) from the SGX-ST in respect of the listing of and quotation for the Repayment Shares, being an aggregate of 2,492,362 Shares, on the Catalist of the SGX-ST, subject to the Company’s compliance with the SGX-ST’s listing requirements. The Repayment Shares have to be placed out within seven (7) market days from the date of the LQN.

The LQN from the SGX-ST is not to be taken as an indication of the merits of the Repayment Shares, the repayment of Loans via the issue and allotment of the Repayment Shares, the Company and/or its subsidiaries.

Further announcements will be made by the Company as and when appropriate.

BY ORDER OF THE BOARD

Dr Djeng Shih Kien  
Executive Director and Chief Executive Officer  
21 June 2024

---

Singapore Institute of Advanced Medicine Holdings Ltd. (the “Company”) was listed on Catalist of the Singapore Exchange Securities Trading Limited (“SGX-ST”) on 16 February 2024. The initial public offering of the Company was sponsored by PrimePartners Corporate Finance Pte. Ltd. (the “Sponsor”).

This announcement has not been examined or approved by the SGX-ST. The SGX-ST assumes no responsibility for the contents of this document, including the correctness of any of the statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Ms. Ng Shi Qing, 16 Collyer Quay, #10-00 Collyer Quay Centre, Singapore 049318, [sponsorship@ppcf.com.sg](mailto:sponsorship@ppcf.com.sg).